OncoBay Clinical, one of Moffitt Cancer Center’s for-profit subsidiaries, has partnered with Clinscience, a global clinical research organization based in Warsaw, Poland. The investment gives NEUCA Group, Clinscience’s parent company, a majority equity stake in OncoBay. Both companies will work together to advance immuno-oncology research for a global portfolio of clients.
Moffitt created OncoBay in 2019 as a boutique clinical research organization that offers streamlined, custom-curated services for biopharma and biotech companies conducting research in the immuno-oncology space. Since its initial launch three years ago, OncoBay has transformed from a concept to a global entity with more than 60 customers, with many trials conducted in tandem with Clinscience. This new partnership builds upon a two-year relationship with Clinscience.
"Moffitt made an investment three years ago when it launched OncoBay, and in that short period of time we have taken this concept to a global entity with an international research footprint. This new partnership with Clinscience will allow us to continue to provide tailored immuno-oncology on a much larger scale."- James Mulé, PhD, ACD of Translational Science at Moffitt and OncoBay advisor
This investment gives NEUCA Group, Clinscience’s parent company, a majority equity stake in OncoBay. Moffitt will continue our close relationship and collaboration with OncoBay, and this partnership will allow us to provide tailored immuno-oncology on a much larger scale and reach patients more quickly.
If you'd like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.